[{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics Announces the Selection of PRTX007 for COVID-19 and Oncology Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"CAM Capital","pharmaFlowCategory":"D","amount":"$27.4 million","upfrontCash":"Undisclosed","newsHeadline":"Primmune Therapeutics Announces $27.4 Million Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics to Present Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics Presents Interim Analysis of Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","amount":"$22.5 million","upfrontCash":"Undisclosed","newsHeadline":"Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Primmune Therapeutics
The net proceeds will be used to develop PRTX007, a clinical-stage novel oral small molecule, as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.
PRTX007 is Primmune’s lead clinical development candidate that is designed to provide well tolerated, controlled, long-term stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses.
Findings demonstrate broad-spectrum antiviral activity and suitability of PRTX007, also exhibits activation of the innate immune system in both cellular and murine animal models against respiratory syncytial virus (RSV).
Oral administration of PRTX007 in this first-in-human study of healthy volunteers exhibited a favorable safety profile, rapid absorption and conversion to TLR7 agonist PRX034, and activation of the innate immune system, without causing inflammation.
PRTX007 is designed to provide immediate benefit to patients through controlled stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses.
The fund will be used to support the further clinical development of PRTX007 as a TherAjuvant™ for acute viral diseases, pre-cancerous lesions, and advanced cancer. PRTX007 is a novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonist.
PRTX007 is Primmune’s lead TherAjuvant™ small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including SARS-CoV-2, and cancer.
This financing will enable the company to move PRTX007 into a short-term pharmacokinetic, pharmacodynamic and tolerability study in humans to be followed by a clinical proof-of-concept study in an acute viral disease setting.
PRTX007 derived from Primmune's extensive TLR7 agonist discovery program, has demonstrated sustained dose-dependent innate immune induction in vivo without the production of inflammatory cytokines.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
